Rezera launches REVEAL-PAD study to map inflammation in PAD
Rezera has announced plans to launch REVEAL-PAD, a prospective, multi-centre observational study examining the role of inflammation in peripheral artery disease (PAD). The study is designed to build an eligible patient cohort and generate real-world disease data in advance of the company's planned Phase 3 registrational trial of ruvonoflast, its oral NLRP3 inhibitor, which Rezera expects to initiate in the first half of 2027.
The study's full name, Real-world Evaluation of Vascular Events and Limb Outcomes in Peripheral Artery Disease, signals its scope. REVEAL-PAD will be led by a steering committee drawn from Rezera, the Colorado Prevention Center (CPC) Clinical Research, and the Duke Clinical Research Institute. The primary objectives are to quantify residual inflammatory burden in symptomatic PAD patients receiving standard of care, and to identify individuals who may qualify for the forthcoming interventional programme.
The scientific case for an NLRP3 target in PAD
PAD affects an estimated 200 million people worldwide and is characterised by progressive atherosclerotic obstruction of the peripheral arteries, causing symptoms ranging from claudication to critical limb ischaemia. Despite the scale of the problem, approved therapies address risk factors and revascularisation rather than the underlying inflammatory pathology. Rezera's thesis is that NLRP3 inflammasome activation drives residual vascular inflammation even in patients on contemporary guideline-directed therapy, and that ruvonoflast can reduce that burden.
Marc Bonaca, Professor of Medicine and Director of Vascular Research at the University of Colorado School of Medicine and Executive Director of CPC, said the observational study would provide "an outstanding resource to enable better understanding of functional limitations as well as its clinical and biomarker correlates" and could serve as a novel route to accelerate enrolment in the subsequent interventional trial.
The NLRP3 pathway has attracted considerable pharmaceutical attention since the CANTOS trial demonstrated that targeting IL-1 beta reduced cardiovascular events. A number of companies, including Novartis with canakinumab and smaller players developing oral small-molecule NLRP3 inhibitors, are active in the cardiovascular inflammation space. Rezera's focus on an oral agent is positioned by the company as a practical advantage over injectable biologics in a chronic-disease setting.
Pipeline context and near-term milestones
Rezera's development timeline is active beyond REVEAL-PAD. The company recently reported topline data from its Phase 2 RESOLVE-1 study of ruvonoflast, and expects topline results from the related RESOLVE-2 study in the fourth quarter of 2026. A second asset, trabzanoflast, is in development for neurological indications, with Phase 1 topline data also expected in Q4 2026. The pair of readouts makes the coming months a significant data window for the Boston-based biotech.
For REVEAL-PAD itself, the commercial logic extends beyond trial acceleration. Longitudinal real-world data on PAD progression and healthcare resource use have value to payors and health systems independently of Rezera's clinical programme, potentially supporting health-economic arguments for a future reimbursement submission. Whether the study generates enough biomarker signal to sharpen patient selection for Phase 3 will be a key question for analysts watching the asset.
Rezera is headquartered in Boston, with an R&D base in Cambridge, UK. The company is privately held and has not disclosed funding details in this announcement.